That leap didn't happen by accident. It happened because Next-Generation Sequencing (NGS) replaced slow, one-fragment-at-a-time Sanger sequencing with massively parallel technology that reads millions of DNA fragments at once.
This article covers what NGS actually is, the generations of sequencing technology behind it, how the workflow operates, where it's applied, and why researchers trust it. We'll also touch on how imaging tools fit into modern genomic sample prep.
Key Takeaways
- NGS sequences millions of DNA/RNA fragments at once, unlike Sanger’s single-fragment method
- Sequencing “generations” force tradeoffs among read length, accuracy, speed, and cost
- Labs apply NGS in cancer research, infectious disease, reproductive health, and agriculture
- Higher sample purity—and better imaging-guided prep—yield cleaner NGS inputs
What Is Next-Generation DNA Sequencing?
Next-generation sequencing (NGS) is a high-throughput, massively parallel sequencing technology. It determines the order of nucleotides across millions of DNA or RNA fragments at the same time, rather than processing one fragment per run.
Sanger sequencing, the first-generation method, reads one DNA template per capillary using chain-terminating nucleotides (Sanger method review). It's accurate, but slow at scale. That's why the Human Genome Project needed over a decade and billions of dollars to finish.
NGS works differently. The core principle:
- Fragment the DNA into small pieces
- Sequence all fragments in parallel
- Reassemble the sequence using bioinformatics software that aligns reads against a reference genome
Since NGS platforms entered production around 2008, the cost per genome has fallen dramatically. NHGRI's tracked data (assuming 30x coverage) shows this decline began exactly when second-generation platforms scaled up (NHGRI cost data).
You'll also see NGS called "high-throughput sequencing" or "deep sequencing." These terms are related but not always interchangeable. "Deep" typically refers to coverage depth, while "high-throughput" and "massively parallel" emphasize scale (NGS terminology review). Knowing the distinction matters when comparing platform specs or reading methods sections in papers.
This guide covers how NGS works, where it outperforms earlier methods, and what to weigh when you plan sequencing workflows.
The Generations of Sequencing Technology
First-Generation Sequencing (Sanger)
Sanger sequencing separates fluorescently labeled DNA fragments by capillary electrophoresis. It remains highly accurate for single targets and is still used for confirmatory testing today. Its main limit was throughput, not precision: one capillary, one template, one read at a time.
Second-Generation Sequencing (Short-Read NGS)
Second-generation platforms made "massively parallel" sequencing practical. Key platforms include:
- Illumina sequencing-by-synthesis: bridge-amplified clusters and XLEAP-SBS chemistry on NovaSeq X systems; reads from 2x50 to 2x300 bp (Illumina specs)
- 454 pyrosequencing: detected pyrophosphate release; reads of 600–800 nt at 99%+ accuracy before the platform was discontinued (PMC)
- Ion Torrent: detects pH changes from H+ release during incorporation, with no optical detection required
These platforms rely on clonal amplification — copying each fragment thousands of times so the signal is strong enough to detect.
Third and Fourth-Generation Sequencing (Long-Read/Single-Molecule)
Long-read platforms sequence native DNA molecules directly, without amplification:
- PacBio SMRT/HiFi: real-time single-molecule reads in zero-mode waveguides; consensus averages 13.5 kb at 99.8% accuracy via repeated passes (PubMed, 2019)
- Oxford Nanopore: measures ionic current as DNA passes through a pore; a 2023 SARS-CoV-2 benchmark reported 98.34% average accuracy for R10.4 chemistry (PMC, 2023)
The trade-off: long reads greatly improve structural variant detection and genome assembly, especially in repetitive regions short reads cannot resolve. Early long-read methods carried higher per-base error rates, though HiFi consensus sequencing has narrowed that gap considerably.
There's no single agreed definition of "fourth generation." Some reviews use it for nanopore sequencing specifically; others reserve it for methods preserving spatial sequence context. Treat the label loosely.
How Next-Generation Sequencing Works: The NGS Workflow
Illumina defines four core workflow steps (Illumina):
Step 1: Nucleic Acid Extraction
Pure DNA or RNA must be isolated from cells first. Contaminated or degraded starting material undermines every later step, so extraction quality sets the ceiling for the entire run.
Step 2: Library Preparation
Samples are fragmented, adapters are ligated onto the fragment ends, and libraries are size-selected to match the sequencer's requirements.
Step 3: Sequencing
The instrument performs clonal amplification (for short-read platforms) and reads millions of fragments in parallel, calling bases as it goes.
Step 4: Bioinformatics Analysis
Reads are aligned to a reference genome, variants are called, and results are visualized for interpretation.
Where imaging fits in: Before extraction, researchers often need pure target cells from mixed tissue, such as a tumor region next to healthy cells. Laser capture microdissection systems like Laxco's Accuva Cellect isolate those cells so the library reflects the population you intend to sequence.
Imaging also supports the cell-identification work that feeds histology and biomarker studies ahead of molecular processing. Laxco's LEAP AI platform pairs Accuva LEAP optics with Image-Pro AI analysis for those pre-analytical imaging steps, helping labs move from tissue section to a defined genomic sample with fewer manual handoffs.
Key Applications of Next-Generation Sequencing
NGS shows up wherever labs need high-throughput reads—from tumor profiling and outbreak tracking to prenatal screening and crop genetics.
Cancer research still drives much of the clinical demand. Teams use NGS to find mutations, gene fusions, and copy number changes that guide therapy choices. FoundationOne Liquid CDx targets 324 genes from plasma cfDNA. Validation across more than 7,500 tests showed 96.3% positive percent agreement and 99.59% reproducibility (PMC).
Public health labs lean on the same throughput for infectious disease surveillance. In 2019, the CDC made whole-genome sequencing PulseNet’s gold standard for foodborne pathogen tracking, so outbreaks link back to their source faster (CDC).
Reproductive and hereditary disease work applies NGS in focused panels and broader exomes:
- Non-invasive prenatal testing (NIPT) with ~99.3% sensitivity for trisomy 21 and specificity above 99.96%
- Exome sequencing that reaches a diagnosis in roughly 30–50% of rare Mendelian cases, depending on cohort and phenotype
- Carrier and hereditary cancer panels that flag actionable variants before symptoms appear
Scale matters just as much outside the clinic. The 2018 3,000 Rice Genomes Project sequenced 3,010 accessions and found 29 million SNPs used to map traits such as grain size and bacterial-blight resistance (Nature)—a clear case of agricultural genomics running on NGS at population scale.
Why Researchers Choose NGS: Advantages and Accuracy
Compared to Sanger sequencing or microarrays, NGS offers:
- No prior genome knowledge required — unlike arrays, which need known probes
- Single-nucleotide resolution across the entire sequenced region
- Higher reproducibility across large sample sets
- Lower input requirements, down to nanogram quantities of DNA
Accuracy Depends on the Whole Pipeline, Not Just the Platform
Accuracy claims need context. NovaSeq X requires at least 85% of bases above Q30 for standard 2x150 bp runs. That figure is a per-base quality metric, not end-to-end variant-call accuracy (Illumina).
Coverage depth matters too. A 2021 clinical WGS study found SNV sensitivity plateaued near 40x coverage, and even at nearly 150x depth, accuracy never reached 100% (PMC). Throwing more coverage at a sample only helps so much. Quality filtering and pipeline design matter as much as raw sequencing power.
Sample purity going in affects accuracy coming out. Contaminated or mixed-cell inputs make variant calling murkier, regardless of platform. That is why pairing sequencing with precise upstream isolation matters:
- Laxco's Accuva Cellect uses a contact-free IR laser to capture single cells or small populations while preserving morphology and nucleic-acid integrity
- UV laser mode handles denser tissue (bone, plant) with speed and precision
- Target-only isolation from FFPE and fresh-frozen samples yields purer input than whole-tissue homogenization and supports clearer downstream variant calls, recovering usable material from picogram quantities down to single cells
Frequently Asked Questions
What does next-generation sequencing tell you?
NGS reveals the precise order of nucleotides in DNA or RNA, letting researchers detect mutations, structural variants, gene expression patterns, and epigenetic changes relevant to disease or research questions.
How accurate is next-generation sequencing?
Accuracy varies by platform, sequencing depth, and quality filtering. Modern platforms achieve high per-base accuracy suitable for research and clinical-grade variant detection, though depth and pipeline design affect real-world results.
What is 4th generation sequencing?
It usually means single-molecule, real-time methods such as nanopore sequencing, which read native DNA without amplification. There is no fixed definition; some reviews treat it as an extension of third-generation methods.
What are examples of next-generation sequencing?
Common platforms include Illumina sequencing-by-synthesis, Ion Torrent semiconductor sequencing, 454 pyrosequencing (now discontinued), and long-read options like Oxford Nanopore and PacBio.
How much does next-generation sequencing cost?
Costs have dropped substantially over two decades. Pricing varies by platform, coverage depth, and scope: targeted gene panels cost far less than whole-genome sequencing. Get quotes directly from an accredited lab for current pricing.
What is the difference between NGS and Sanger sequencing?
Sanger sequences one DNA fragment at a time with high per-read accuracy but low throughput. NGS sequences millions of fragments in parallel, so large genomic projects finish faster and cost less per base.